No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
323 |
4. Check minimum number of eventsNone |
323 |
5. Include endpointsNone |
323 |
6. Filter based on genotype QC (FinnGen only) |
323 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E23
- Name in latin
- Diabetes insipidus
Similar endpoints
↥List of similar endpoints to
Diabetes insipidus
based on the number of shared cases.
Similar with more cases:
- Exclusions for E4_PCOS_BROAD
- Developmental endpoint to exclude non autoimmune-cases from E4_HYTHY_AI_STRICT
- Disorders of other endocrine glands
- Used for control exclusion in common control thyroid runs
- Endocrine, nutritional and metabolic diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1936 | 1022 | 905 |
| Only index persons | 1614 | 884 | 730 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 43.88 | 45.33 | 42.11 |
| Only index persons | 42.57 | 44.24 | 40.55 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 323 | 200 | 123 |
| Unadjusted period prevalence (%) | 0.06 | 0.07 | 0.05 |
| Median age at first event (years) | 47.00 | 45.52 | 49.40 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 288
- Matched controls
- 2878
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
323.0
259
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
311.8
236.4
216
27
102
Kela drug reimbursment
Diabetes insipidus
+∞
224.4
185
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
74.2
68
*
H02AB09
ATC
hydrocortisone; systemic
84.5
73.1
80
13
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
71.9
66
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
+∞
65.1
60
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
160.5
61.7
63
5
2535A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Diabetes insipidus
+∞
37.3
35
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
+∞
36.2
34
*
H03AA01
ATC
levothyroxine sodium; systemic
5.1
32.4
130
400
R63.1
ICD-10 Finland
Polydipsia
+∞
30.8
29
*
25390
ICD-8 Finland
Diseases of pituitary gland, Diabetes insipidus
+∞
30.8
29
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
15.4
28.1
47
36
R35
ICD-10 Finland
Polyuria
9.2
23.2
50
64
H01AC01
ATC
somatropin; parenteral
+∞
22.2
21
*
E87.0
ICD-10 Finland
Hyperosmolality and hypernatraemia
56.4
18.2
21
*
N05AN01
ATC
lithium; oral
18.9
17.3
26
15
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.6
17.2
53
112
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
+∞
16.8
16
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
11.4
16.7
31
30
H53.4
ICD-10 Finland
Visual field defects
14.0
16.5
28
22
XCK00
NOMESCO Finland
Perimetry
6.7
16.2
42
71
N25.1
ICD-10 Finland
Nephrogenic diabetes insipidus
+∞
15.8
15
*
301
Kela drug reimbursment
Growth hormone
+∞
15.8
15
*
D35.30
ICD-10 Finland
Craniopharyngoma
+∞
15.8
15
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.0
15.3
29
29
E89.30
ICD-10 Finland
Postprocedural hypopituitarism
+∞
14.7
14
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
6.6
13.9
36
61
AA1AD
NOMESCO Finland
CT of head and brain
3.2
13.8
86
342
E23.05
ICD-10 Finland
Lack of TSH
+∞
13.6
13
*
TAB00
NOMESCO Finland
Lumbar puncture
7.2
13.6
33
51
E23.02
ICD-10 Finland
Neurosecretory dysfunction of the growth hormone
+∞
12.6
12
*
E23.6
ICD-10 Finland
Other disorders of pituitary gland
+∞
11.5
11
*
E23.09
ICD-10 Finland
Pituitary insufficiency NOS
+∞
11.5
11
*
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
+∞
11.5
11
*
E23.0
ICD-10 Finland
Hypopituitarism
+∞
11.5
11
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.2
11.5
66
242
R51.80
ICD-10 Finland
Headache
3.3
11.3
63
228
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
114.0
10.5
11
*
9350/1-C75.2
ICD-O-3
Craniopharyngioma, NOS, of craniopharyngeal duct
+∞
10.5
10
*
E23.03
ICD-10 Finland
Lack of ACTH
+∞
10.5
10
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
24.4
10.3
14
6
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
13.8
10.3
17
13
N05BA01
ATC
diazepam; systemic, rectal
3.2
9.9
55
197
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
3.3
9.7
51
176
N03AG01
ATC
valproic acid; systemic, rectal
4.6
9.7
33
78
N05AA02
ATC
levomepromazine; systemic
6.0
9.6
26
47
ZXC86
NOMESCO Finland
Use of endoscopic device
31.2
9.5
12
*
AA4DG
NOMESCO Finland
Very extensive MRI examination of sella turcica with high intensity magnet
+∞
9.4
9
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
4.0
9.0
36
100
N91.1
ICD-10 Finland
Secondary amenorrhoea
14.6
8.8
14
10
E22.1
ICD-10 Finland
Hyperprolactinaemia
92.7
8.5
9
*
N05AH03
ATC
olanzapine; systemic
4.1
8.4
32
85
E23.3
ICD-10 Finland
Hypothalamic dysfunction, not elsewhere classified
+∞
8.4
8
*
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
8.4
8
*
2542
FHL
Transasal hypophysectomy
+∞
8.4
8
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.7
8.2
62
267
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
8.2
74
355
R50.9
ICD-10 Finland
Fever, unspecified
3.0
8.2
50
191
A06AD11
ATC
lactulose; oral
3.0
8.0
46
169
R42
ICD-10 Finland
Dizziness and giddiness
2.5
7.9
70
330
R60.0
ICD-10 Finland
Localized oedema
3.2
7.8
41
142
N04BC06
ATC
cabergoline; oral (dopamine agonists)
46.3
7.8
9
*
G04BD04
ATC
oxybutynin; oral, transdermal
4.7
7.7
25
57
A12BA01
ATC
potassium chloride; oral
5.6
7.5
21
40
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
82.1
7.5
8
*
N05AH04
ATC
quetiapine; oral
2.5
7.4
60
271
R33
ICD-10 Finland
Retention of urine
3.9
7.3
29
80
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
7.3
7
*
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
7.3
7
*
25310
ICD-8 Finland
Diseases of pituitary gland, Panhypopituitarismus
+∞
7.3
7
*
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
+∞
7.3
7
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.3
7.3
36
119
N03AX14
ATC
levetiracetam; systemic
6.3
7.2
18
30
H47.2
ICD-10 Finland
Optic atrophy
30.9
7.2
9
*
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
20.6
7.2
10
5
R53
ICD-10 Finland
Malaise and fatigue
2.4
7.0
67
327
L28
ICPC
Limited function/disability (L)
2.6
7.0
51
217
N05CD07
ATC
temazepam; oral
2.9
7.0
44
171
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
7.0
39
140
ZXC95
NOMESCO Finland
Use of surgical navigator
14.2
6.9
11
8
WX882
NOMESCO Finland
High dependency care
7.0
6.9
16
24
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
6.7
87
489
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
6.7
121
777
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.7
6.5
45
186
N05BA04
ATC
oxazepam; oral
2.1
6.5
81
448
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
7.7
6.5
14
19
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.7
6.4
44
180
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.5
6.4
21
49
2532A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Panhypopituitarism[PANHYPOPITUITARISMUS]
+∞
6.3
6
*
E23
ICD-10 Finland
Hypofunction and other disorders of pituitary gland
+∞
6.3
6
*
E23.06
ICD-10 Finland
Empty sella
+∞
6.3
6
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
6.5
6.2
15
24
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
6.5
6.2
15
24
UKC02
NOMESCO Finland
Cystoscopy
2.5
6.1
48
212
N06AA09
ATC
amitriptyline; systemic
2.9
6.1
35
129
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
5.8
6.1
16
29
Z01.8
ICD-10 Finland
Other specified special examinations
2.2
6.0
67
350
C02AC05
ATC
moxonidine; oral
5.0
6.0
18
38
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.4
6.0
53
250
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.0
6.0
34
123
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.2
6.0
65
337
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
121
24
80.02
219.18
3.8
1.2
294.0
277.6
mosm/kgh2o
2.48
104
17
163
251
12.09
113.45
5.3
1.7
299.4
382.5
nmol/l
4.31
153
232
54
69
9.20
40.86
2.3
1.1
8.1
8.9
u/l
0.18
44
56
237
1210
4.60
34.94
10.2
6.8
1.2
1.2
mmol/l
0.57
193
1035
219
1100
4.08
31.97
10.2
6.2
1.2
1.2
mmol/l
0.33
203
1014
35
38
10.21
29.69
2.6
1.4
0.2
0.3
nmol/l
0.28
28
30
68
164
4.99
27.24
4.3
1.9
13.1
13.5
nmol/l
0.13
62
151
25
22
12.23
24.30
2.0
1.1
—
—
—
0
0
34
62
6.01
18.32
1.6
1.2
426.3
7.2
e6/l
0.49
23
50
34
62
6.01
18.32
1.7
1.3
1365.6
199.4
e6/l
0.83
24
51
96
390
3.08
17.54
3.4
3.4
0.8
0.8
mmol/l
1.03
90
369
47
123
4.30
16.68
2.2
1.3
16.3
23.8
iu/l
0.72
37
101
275
2051
3.29
13.99
8.5
3.8
15.1
14.6
pmol/l
1.75
262
1877
67
266
2.92
12.39
10.0
10.6
1.1
1.3
mmol/l
0.13
53
220
204
1368
2.33
11.96
5.7
5.8
9.2
10.8
umol/l
2.81
197
1298
20
33
6.39
11.80
1.1
1.0
—
—
—
0
0
150
912
2.20
10.83
4.2
2.9
—
—
—
0
0
12
12
10.35
10.50
1.2
1.0
—
—
—
0
0
167
1076
2.14
10.23
3.5
2.2
77.5
76.1
nmol/l
0.29
152
963
14
18
8.08
10.22
1.0
1.0
—
—
—
0
0
212
1501
2.20
10.13
8.3
4.8
6.6
6.6
mmol/l
0.07
198
1397
19
35
5.71
10.05
1.1
1.0
—
—
—
0
0
50
199
2.79
9.09
7.8
4.1
1.7
2.3
mmol/l
0.74
43
155
17
31
5.73
9.07
1.1
1.0
—
—
—
0
0
132
806
2.08
9.03
3.0
2.3
85.2
55.1
u/l
0.42
119
740
70
330
2.43
9.02
2.8
2.2
2.4
2.4
g/l
0.15
63
305
66
306
2.45
8.81
2.9
2.2
26.0
23.3
%
0.42
56
267
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
11
14
8.10
8.03
1.3
1.1
—
—
—
0
0
115
696
2.01
7.84
3.4
2.8
1.1
0.4
e6/l
0.57
94
521
71
359
2.25
7.72
2.8
2.2
14.8
13.6
umol/l
0.32
66
328
131
837
1.95
7.60
3.7
3.1
2.3
2.4
mmol/l
0.71
119
743
11
7
16.20
7.28
2.6
1.0
2.4
5.7
umol/l
—
11
7
14
27
5.37
7.03
1.6
1.2
—
—
nmol/l
—
0
0
11
8
14.18
6.94
2.3
1.0
—
—
—
0
0
37
148
2.69
6.63
9.3
7.1
24.5
25.1
mmol/l
0.47
37
148
142
969
1.83
6.46
2.0
1.9
109.3
96.2
pmol/l
1.54
71
503
98
595
1.93
6.43
2.2
1.9
2.9
3.1
mg/l
0.48
89
510
71
387
2.07
6.30
2.2
1.8
—
—
—
0
0
251
2053
2.00
6.28
9.3
6.8
80.0
76.1
u/l
0.77
242
1919
27
94
3.04
6.21
1.6
2.0
—
—
—
0
0
36
148
2.61
6.12
6.8
4.3
2.3
1.9
mmol/l
0.24
29
114
25
85
3.10
5.99
1.7
1.8
—
—
—
0
0
39
171
2.46
5.81
2.0
1.4
—
—
—
0
0
82
484
1.93
5.78
1.8
1.8
467.9
438.8
pmol/l
0.47
67
421
241
1978
1.86
5.53
5.2
3.9
11.5
10.7
mm/h
0.49
225
1830
282
2443
2.22
5.50
7.6
5.4
39.9
39.5
mmol/mol
0.25
268
2298
91
564
1.85
5.50
1.6
1.5
22.1
20.7
nmol/l
0.34
75
481
103
666
1.80
5.41
3.5
3.1
976.5
971.4
ng/l
0.01
88
558
283
2468
2.18
5.22
8.2
4.5
1.6
1.9
mu/l
2.94
255
2262
200
1569
1.72
5.20
11.9
8.9
4.6
4.0
e9/l
2.30
186
1375
11
23
4.92
5.05
1.5
1.6
—
—
—
0
0
54
289
2.04
4.99
2.1
2.4
4.9
7.4
umol/l
0.97
44
247
92
589
1.79
4.94
2.6
2.2
—
—
—
0
0
285
2516
2.13
4.70
20.8
11.3
83.1
84.4
ml/min/173m2
0.41
258
2029
20
70
2.98
4.58
1.4
1.4
0.1
0.1
iu/ml
—
7
11
175
1357
1.63
4.48
5.0
3.4
0.0
0.0
estimate
0.50
39
239
289
2578
2.15
4.42
5.9
4.3
5.9
5.9
mmol/l
0.04
273
2381
154
1164
1.62
4.33
3.5
2.6
122.1
100.8
ug/l
0.48
146
1076
124
889
1.64
4.31
3.8
2.9
38.2
30.5
u/l
0.55
118
854
7
6
11.88
4.29
1.3
1.0
—
—
—
0
0
131
954
1.63
4.27
4.8
3.4
36.0
37.8
ng/l
0.05
99
615
30
135
2.35
4.24
1.5
1.3
—
—
—
0
0
171
1334
1.60
4.16
5.1
3.3
0.0
0.0
estimate
0.00
37
244
172
1345
1.60
4.13
6.0
4.6
0.0
0.0
estimate
0.00
38
245
12
33
3.74
3.96
1.1
1.1
—
—
—
0
0
43
233
1.98
3.83
3.9
3.0
—
—
—
0
0
6
5
12.19
3.77
1.2
1.0
—
—
—
0
0
17
61
2.89
3.75
8.5
3.7
8.9
8.1
kpa
0.91
17
56
85
574
1.65
3.65
1.9
1.7
1.1
1.1
mg/l
0.08
62
440
28
131
2.25
3.64
1.9
1.6
—
—
—
0
0
65
411
1.73
3.56
3.1
2.5
0.7
0.9
e6/l
0.47
41
227
6
6
10.16
3.51
1.3
1.0
—
—
—
0
0
6
6
10.16
3.51
1.3
1.0
—
—
—
0
0
6
7
8.70
3.27
2.0
1.9
13.9
19.9
umol/l
—
6
7
293
2686
1.98
3.23
23.2
12.3
19.5
21.8
mg/l
0.75
248
2091
17
67
2.62
3.18
4.3
2.7
—
—
—
0
0
23
105
2.28
3.17
1.4
1.4
0.8
1.3
u/ml
—
7
8
99
717
1.55
3.13
6.5
3.7
0.0
0.0
estimate
0.50
38
243
135
1047
1.50
3.09
5.5
3.4
—
—
—
0
0
89
632
1.56
3.06
1.5
1.3
3.2
1.6
u/ml
0.43
22
170
65
428
1.65
3.05
2.0
1.6
1193.7
1165.5
nmol/l
0.10
52
325
7
12
5.94
3.03
1.0
1.0
—
—
—
0
0
5
5
10.13
2.99
1.0
1.4
—
—
—
0
0
5
5
10.13
2.99
1.2
1.0
—
—
—
0
0
7
13
5.48
2.88
1.6
3.4
623.0
886.3
u/ml
—
7
13
59
389
1.63
2.75
3.5
2.6
3.3
2.8
e6/l
0.14
32
208
30
163
1.93
2.68
2.4
3.0
92.9
148.1
ng/l
0.90
25
145
213
1844
1.46
2.59
4.5
2.9
44.1
44.4
u/l
0.03
200
1739
44
273
1.71
2.58
2.3
1.7
—
—
—
0
0
21
104
2.09
2.42
1.5
2.4
—
—
—
0
0
16
71
2.32
2.38
1.5
1.1
—
—
—
0
0
10
35
2.92
2.32
1.8
1.3
—
—
—
0
0
11
42
2.68
2.21
1.1
1.1
—
—
—
0
0
6
14
4.35
2.16
1.0
1.2
—
1.1
—
0
5
8
25
3.25
2.11
1.1
1.2
—
—
—
0
0
8
25
3.25
2.11
1.1
1.2
—
—
—
0
0
8
25
3.25
2.11
1.4
2.2
—
—
—
0
0
9
31
2.96
2.09
3.4
6.4
—
4198.3
—
0
6
5
10
5.06
2.08
1.2
1.4
—
—
—
0
0
47
315
1.58
2.06
4.6
4.1
33.7
31.1
%
0.63
38
216
13
268
0.46
2.04
1.5
1.7
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
42
276
1.60
2.00
2.5
1.7
—
—
—
0
0
15
71
2.17
1.95
1.3
1.1
—
—
—
0
0
8
27
3.01
1.95
1.5
2.1
—
—
—
0
0
144
1209
1.34
1.86
4.3
3.9
—
—
—
0
0
62
452
1.46
1.85
4.2
3.4
445.2
216.0
ng/l
0.55
44
329
5
12
4.21
1.83
1.2
1.1
—
—
—
0
0
13
60
2.22
1.80
1.3
1.7
—
—
—
0
0
13
60
2.22
1.80
2.4
2.3
45.7
103.8
ug/min
—
7
34
5
13
3.89
1.72
1.0
1.0
—
—
—
0
0
0
47
0.00
1.72
0.0
1.4
—
—
—
0
0
7
26
2.73
1.59
21.1
20.2
1140.3
1585.3
nmol/l
—
7
26
7
26
2.73
1.59
14.1
14.1
519.6
847.1
nmol/l
—
7
26
17
93
1.87
1.54
1.4
1.5
—
—
—
0
0
12
58
2.11
1.51
1.3
1.8
—
—
—
0
0
82
658
1.33
1.39
2.6
2.7
361.3
7117.0
umol/l
3.14
67
573
6
23
2.64
1.37
1.3
1.2
—
—
—
0
0
5
18
2.80
1.29
1.2
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
55
2.04
1.29
2.0
3.1
0.4
0.3
u/ml
—
5
28
9
44
2.07
1.28
1.0
1.3
—
—
—
0
0
9
44
2.07
1.28
1.0
1.3
—
—
—
0
0
8
36
2.25
1.25
1.3
1.7
—
—
—
0
0
81
660
1.30
1.23
4.8
4.4
3.0
2.2
ug/l
0.28
72
594
13
71
1.87
1.21
2.0
1.7
—
—
—
0
0
6
26
2.33
1.19
1.2
1.4
—
—
—
0
0
88
731
1.28
1.15
1.6
1.7
1.5
1.4
mmol/l
0.31
76
628
12
65
1.88
1.15
1.5
1.3
—
—
—
0
0
46
350
1.37
1.11
2.1
1.9
1.5
1.5
%
0.01
40
313
11
59
1.89
1.08
1.4
1.3
—
—
—
0
0
269
2555
1.32
1.05
4.7
3.8
1.4
1.3
mmol/l
1.74
250
2369
5
22
2.29
1.03
1.4
1.7
32.0
17.0
ug/l
—
5
22
200
1843
1.22
0.98
3.4
3.2
—
—
—
0
0
5
23
2.19
0.98
1.4
2.0
—
—
—
0
0
74
617
1.26
0.94
6.2
3.4
1.0
1.0
kg/l
1.87
12
83
39
300
1.34
0.90
10.3
6.3
—
—
—
0
0
8
43
1.88
0.88
1.4
1.6
—
—
—
0
0
6
30
2.02
0.87
1.0
1.7
—
—
—
0
0
23
163
1.44
0.84
1.3
1.3
64.7
309.8
u/ml
1.01
23
148
24
324
0.72
0.79
1.9
1.8
—
—
—
0
0
27
356
0.74
0.77
1.7
2.0
—
—
—
0
0
26
194
1.37
0.74
3.1
2.5
3.4
5.5
ug/l
1.30
20
173
13
84
1.57
0.73
1.0
1.1
—
15.8
—
0
12
296
2878
1.34
0.72
14.6
9.5
27.1
26.7
u/l
0.16
291
2786
275
2652
1.25
0.70
5.2
4.3
4.6
4.8
mmol/l
1.24
258
2483
9
59
1.54
0.69
2.6
1.5
—
—
—
0
0
7
120
0.57
0.69
1.1
1.5
—
—
—
0
0
10
62
1.63
0.66
1.3
1.3
—
—
—
0
0
8
51
1.58
0.61
1.3
1.4
—
—
—
0
0
38
461
0.80
0.60
1.5
1.4
—
—
—
0
0
8
52
1.55
0.60
1.1
1.4
—
100.3
—
0
9
20
149
1.36
0.59
1.0
1.0
—
—
—
0
0
6
35
1.73
0.58
11.2
2.3
12.9
13.2
%
—
6
35
273
2644
1.21
0.58
5.2
4.2
1.4
1.5
mmol/l
1.72
254
2461
25
194
1.31
0.58
1.1
1.2
98.2
147.2
iu/ml
—
8
87
26
203
1.31
0.58
2.0
2.8
64.1
73.2
ml/min/173m2
0.46
12
85
13
92
1.43
0.51
1.9
1.9
—
—
—
0
0
277
2699
1.18
0.46
5.7
4.7
2.8
2.8
mmol/l
0.61
259
2507
7
49
1.44
0.46
1.4
1.7
—
—
—
0
0
56
493
1.16
0.44
1.5
1.3
19.4
35.2
iu/ml
1.51
20
154
12
87
1.39
0.43
1.9
1.3
—
—
—
0
0
5
33
1.52
0.41
1.0
1.5
—
—
—
0
0
5
33
1.52
0.41
1.0
1.5
—
—
—
0
0
5
33
1.52
0.41
1.0
1.5
—
—
—
0
0
5
33
1.52
0.41
1.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
4.1
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.2
1.5
—
—
—
0
0
12
90
1.35
0.36
1.0
1.4
164.9
281.8
miu/ml
—
6
47
6
42
1.44
0.35
1.2
1.7
—
—
—
0
0
7
53
1.33
0.31
1.1
1.4
—
—
—
0
0
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
11
88
1.26
0.23
1.4
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
11
90
1.23
0.19
1.4
1.1
—
—
—
0
0
49
523
0.93
0.16
3.9
4.1
23.2
21.3
%
0.34
18
235
35
379
0.91
0.16
3.5
2.7
1.2
0.8
ug/l
0.34
29
233
10
119
0.84
0.15
1.6
1.9
—
—
—
0
0
6
55
1.09
0.09
1.3
1.9
—
—
—
0
0
303
3014
1.09
0.08
36.8
18.4
134.7
136.5
g/l
1.61
303
2974
50
482
1.04
0.07
1.5
1.3
4.3
11.6
u/ml
1.28
22
202
8
93
0.86
0.07
1.3
1.4
—
—
—
0
0
251
2492
1.03
0.06
24.7
13.3
39.1
40.3
%
0.97
163
1902
25
263
0.95
0.05
3.2
4.0
3.7
48.3
ug/l
0.86
19
219
17
159
1.07
0.05
1.3
1.3
—
—
—
0
0
19
180
1.06
0.04
1.6
1.9
—
—
—
0
0
14
149
0.94
0.03
1.5
1.8
—
—
—
0
0
54
530
1.02
0.02
1.5
1.5
—
—
—
0
0
10
95
1.05
0.00
1.3
1.4
—
—
—
0
0
14
136
1.03
0.00
3.6
2.5
0.4
0.1
e6/l
0.54
14
131
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_DIABINSIPIDUS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_DIABINSIPIDUS | 3.239 [2.46, 4.27] | < 0.001 |
| Birth year | 1.001 [0.99, 1.01] | 0.864 |
During the follow-up period (1.1.1998 — 31.12.2019), 127 out of 716 females with E4_DIABINSIPIDUS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_DIABINSIPIDUS | 2.412 [1.78, 3.27] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 595 males with E4_DIABINSIPIDUS died.
Mortality risk
Mortality risk for people of age
years, who have E4_DIABINSIPIDUS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.39% | 0.489% |
| 5 | 2.107% | 3.104% |
| 10 | 5.629% | 7.422% |
| 15 | 10.58% | 13.857% |
| 20 | 18.654% | 22.663% |
Relationships between endpoints
↥Index endpoint: E4_DIABINSIPIDUS – Diabetes insipidus
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data